3-Phenyl-2-piperidino-propionsaeure-methylester | 7012-63-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 3-Phenyl-2-piperidino-propionsaeure-methylester
• 英文别名: 3-phenyl-2-piperidin-1-yl-propionic acid methyl ester；Methyl alpha-benzyl-1-piperidineacetate；methyl 3-phenyl-2-piperidin-1-ylpropanoate
• CAS: 7012-63-7
• 化学式: C₁₅H₂₁NO₂
• 分子量: 247.337
• InChiKey: ZHDGIWAWWUNORR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  18
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  1-benzyl-1-(2-methoxy-2-oxoethyl)piperidinium bromide 以75%的产率得到
  参考文献：
  名称：

  BABAYAN A. T.; KOCHARYAN S. T.; OGANDZHANYAN S. M., AJKAKAN KIMIAKAN AMSAGIR., ARM. XIM. ZH. , 1976, 29, HO 5, 403-4+

  摘要：

  DOI：

文献信息

• [EN] 1-AZA-BICYCLO [2.2.2] OCTANE DERIVATIVES USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS<br/>[FR] DÉRIVÉS DE 1-AZA-BICYCLO [2.2.2] OCTANE UTILES EN TANT QU'ANTAGONISTES DES RÉCEPTEURS MUSCARINIQUES
  申请人：ARGENTA DISCOVERY LTD

  公开号：WO2009153536A1

  公开（公告）日：2009-12-23

  The invention provides named compounds of formula (I), pharmaceutical compositions containing them, a process for preparing the pharmaceutical compositions and their use in therapy.

  本发明提供了公式(I)的命名化合物、含有它们的药物组合物、制备所述药物组合物的方法以及它们在治疗中的用途。
• Facile Approach to Natural or Non-Natural Amino Acid Derivatives: Me₃SiCl-Promoted Coupling Reaction of Organozinc Compounds with N,O-Acetals
  作者：Norio Sakai、Junichi Asano、Yuki Kawada、Takeo Konakahara

  DOI：10.1002/ejoc.200801107

  日期：2009.2

  We have developed a Me3SiCl-promoted coupling reaction of aryl- and alkylzinc compounds, in-situ generated either by transmetalation of the corresponding organometallic reagents or by insertion of zinc metal into organic halides, with several N,O-acetals, which leads to the preparation of a variety of natural and non-natural amino acid derivatives. (© Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim

  我们开发了一种 Me3SiCl 促进的芳基和烷基锌化合物的偶联反应，通过相应的有机金属试剂的金属转移或通过将锌金属插入有机卤化物中而原位生成，与几种 N，O-缩醛，这导致制备多种天然和非天然氨基酸衍生物。(© Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2009)
• PHARMACEUTICAL COMPOSITION COMPRISING A 4-HYDROXY-2-OXO-2, 3- DIHYDRO-1, 3-BENZOTHIAZOL-7-YL COMPOUND FOR MODULATION OF BETA2-ADRENORECEPTOR ACTIVITY
  申请人：AstraZeneca AB

  公开号：EP2303266A1

  公开（公告）日：2011-04-06
• [EN] PHARMACEUTICAL PRODUCT COMPRISING A MUSCARINIC RECEPTOR ANTAGONIST AND A SECOND ACTIVE INGREDIENT<br/>[FR] PRODUIT PHARMACEUTIQUE COMPRENANT UN ANTAGONISTE DU RÉCEPTEUR MUSCARINIQUE ET UN SECOND PRINCIPE ACTIF
  申请人：ASTRAZENECA AB

  公开号：WO2009154554A1

  公开（公告）日：2009-12-23

  The invention provides a pharmaceutical product, kit or composition comprising a first active ingredient which is a selected muscarinic receptor antagonist, and a second active ingredient which is selected from a phosphodiesterase inhibitor, a modulator of chemokine receptor function, an inhibitor of kinase function, a protease inhibitor, a steroidal glucocorticoid receptor agonist, a non-steroidal glucocorticoid receptor agonist and a purinoceptor antagonist, of use in the treatment of respiratory diseases such as chronic obstructive pulmonary disease and asthma.
• [EN] PHARMACEUTICAL COMPOSITION COMPRISING A 4-HYDROXY-2-OXO-2, 3- DIHYDRO-1, 3-BENZOTHIAZOL-7-YL COMPOUND FOR MODULATION OF BETA2-ADRENORECEPTOR ACTIVITY<br/>[FR] COMPOSITION PHARMACEUTIQUE COMPRENANT UN COMPOSÉ 4-HYDROXY-2-OXO-2,3-DIHYDRO-1,3-BENZOTHIAZOL-7-YLE POUR LA MODULATION DE L'ACTIVITÉ DES BÊTA-2-ADRÉNORÉCEPTEURS
  申请人：ASTRAZENECA AB

  公开号：WO2009154562A1

  公开（公告）日：2009-12-23

  The invention provides a pharmaceutical product, kit or composition comprising a first active ingredient which is N-Cyclohexyl-Λ/3-[2-(3-fluorophenyl)ethyl]-Λ/-(2-[2-(4- hydroxy-2-oxo-2,3-dihydro- 1,3-benzothiazol-7-yl)ethyl]amino} ethyl)-β-alaninamide or a salt thereof, and a second active ingredient selected from: a non-steroidal Glucocorticoid Receptor (GR Receptor) Agonist; an antioxidant; a CCRl antagonist; a chemokine antagonist (not CCRl); a corticosteroid; a CRTh2 antagonist; a DPI antagonist; an Histone Deacetylase Inducer; an IKK2 inhibitor; a COX inhibitor; a lipoxygenase inhibitor; a leukotriene receptor antagonist; an MPO inhibitor; a muscarinic antagonist; a p38 inhibitor; a PDE inhibitor; a PPARγ agonist; a protease inhibitor; a Statin; a thromboxane antagonist; a vasodilator; or, an ENAC blocker (Epithelial Sodium-channel blocker); and its use in the treatment of respiratory disease (for example chronic obstructive pulmonary disease (COPD) or asthma); to certain salts of A/-Cyclohexyl-N3-[2-(3-fluorophenyl)ethyl]- N-(2-[2-(4-hydroxy-2-oxo-2,3-dihydro-l,3-benzothiazol-7-yl)ethyl]amino}ethyl)-β- alaninamide and to an intermediate useful in the manufacture of this pharmaceutically active substance and salts thereof.